What question did this study set out to answer?

To determine plasma cyclic guanosine 3':5' monophosphate (cGMP) response to physical exercise with and without the administration of isosorbide-5-mononitrate in coronary patients and healthy controls.

November 1, 1995European Journal of Clinical Investigation

Effect of isosorbide‐5‐mononitrate on plasma and urine levels of cyclic GMP in relation to exercise in coronary patients compared with control subjects

View Full Paper

Ask AI

Bookmark

Why the study?

Does isosorbide-5-mononitrate alter the plasma cGMP response to exercise in coronary patients and healthy controls?

Population

8 coronary patients, 9 healthy control subjects, and 10 normal volunteers (total n=27)

Comparison

20 mg of isosorbide-5-mononitrate administered… vs Exercise without medication and a separate…

Design

Other

Authors

JBJosé R. BerrazuetaPontificia Universidad Católica del Ecuador ESEduardo SalasRice University ARA RiestraUniversidad de Cantabria

Discussion

Member takes

Implication

IS-5-MN blunts exercise cGMP rise in coronary patients and controls; hypothesis-generating for nitrate effects on exercise signaling.

Key Points

To determine plasma cyclic guanosine 3':5' monophosphate (cGMP) response to physical exercise with and without the administration of isosorbide-5-mononitrate in coronary patients and healthy controls.
Evaluated plasma cGMP responses during exercise without medication and following 20 mg of isosorbide-5-mononitrate (IS-5-MN) in coronary patients (n = 8) and healthy controls (n = 9).
Included a third control group of normal volunteers (n = 10) who underwent a second exercise test without IS-5-MN administration.
Baseline exercise significantly increased plasma cGMP in both coronary patients (P < 0.02) and healthy controls (P < 0.01).
Administration of 20 mg IS-5-MN prevented increases in plasma cGMP both at rest and after subsequent exercise in both coronary patients and control subjects.
In normal volunteers tested without IS-5-MN, plasma cGMP significantly rose after both the first (P < 0.004) and second (P < 0.0008) exercise tests.

Structured PICO

Does isosorbide-5-mononitrate alter the plasma cGMP response to exercise in coronary patients and healthy controls?

Population

8 coronary patients, 9 healthy control subjects, and 10 normal volunteers (total n=27)

Intervention

20 mg of isosorbide-5-mononitrate (IS-5-MN) administered before exercise

Comparator

Exercise without medication (first exercise test) and a separate control group of 10 normal volunteers performing a second exercise test without IS-5-MN

Outcome

Plasma and urine levels of cyclic GMP (cGMP) in response to exercisesurrogate

Administration of isosorbide-5-mononitrate blunts the normal exercise-induced increase in plasma cGMP in both coronary patients and healthy controls.

Cite This Study

Berrazueta et al. (1995) studied this question.

synapsesocial.com/papers/6a8a7bb0439f8b7e014351b3 https://doi.org/10.1111/j.1365-2362.1995.tb01695.x

View Full Paper

Ask AI

Bookmark

Effect of isosorbide‐5‐mononitrate on plasma and urine levels of cyclic GMP in relation to exercise in coronary patients compared with control subjects

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Effect of isosorbide‐5‐mononitrate on plasma and urine levels of cyclic GMP in relation to exercise in coronary patients compared with control subjects

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider